tbuckley/cabot-search huggingface dataset:
Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment
Authors: Amy J. Petty, Ang Li, Xinyi Wang, Rui Dai, Benjamin Heyman, David Hsu, Xiaopei Huang, Yiping Yang
Journal: Journal of Clinical Investigation (2019)

Tumor-associated macrophages (TAMs) usually display an antiinflammatory M2-like phenotype to facilitate tumor growth. However, what drives M2 polarization of TAMs and how TAMs suppress antitumor immunity within the tumor microenvironment (TME) remain largely undefined. Using several murine tumor models, we showed that hedgehog (Hh) signaling in myeloid cells is critical for TAM M2 polarization and tumor growth. We also found that tumor cells secrete sonic hedgehog (SHH), an Hh ligand, and that tumor-derived SHH drives TAM M2 polarization. Furthermore, Hh-induced functional polarization in TAMs suppresses CD8+ T cell recruitment to the TME through the inhibition of CXCL9 and CXCL10 production by TAMs. Last, we demonstrated that Krüppel-like factor 4 (Klf4) mediates Hh-dependent TAM M2 polarization and the immunosuppressive function. Collectively, these findings highlight a critical role for tumor-derived SHH in promoting TAM M2 polarization, a mechanism for TAM-mediated immunosuppression, and may provide insights into the design of new cancer immunotherapeutic strategies.
P1.14-12 A Novel Activating MAP2K1 In-Frame Deletion Mediates Acquired Resistance to ROS1 TKIs in a Patient with ROS1 Fusion-Positive NSCLC
Authors: H. Sato, A. Schoenfeld, E. Siau, K. Suzawa, C. Yue, M. Offin, A. Drilon, M. Davare, G. Riely, M. Ladanyi, R. Somwar
Journal: Journal of Thoracic Oncology (2019)
MA16.09 Clinical Practice and Outcomes in Patients with Stage III Unresectable Non-Small-Cell Lung Canceran Academic Centre, Canada
Authors: G. Kasymjanova, D. Small, C. Pepe, L. Sakr, V. Cohen, M. Lecavalier, H. Wang, A. Spatz, M. Hurry, R. Walton, J. Agulnik
Journal: Journal of Thoracic Oncology (2019)
MA03.09 Dramatic Responses to Immune Checkpoint Inhibitors in MET Exon 14 Skipping Mutation (METex14mut) Non Small Cell Lung Cancers
Authors: M. Mayenga, I. Monnet, M. Massiani, J. Assié, L. Tabeze, S. Friard, S. Fraboulet, A. Metivier, C. Chouaid, L. Zemoura, E. Longchampt, S. Melaabi, L. Couderc, H. Doubre
Journal: Journal of Thoracic Oncology (2019)
MA18.07 Identification of Neuroendocrine Transformation in Anaplastic Lymphoma Kinase Rearranged (ALK+) Tumors After Tyrosine Kinase Inhibitors
Authors: P. Pal, A. Fares, D. Patel, E. Stewart, N. Perera-Low, A. Grindley, F. Allison, N. Pham, R. Shi, N. Leighl, F. Shepherd, P. Bradbury, A. Sacher, P. Rogalla, K. Yasufuku, M. Cabanero, M. Tsao, G. Liu, S. Martins-Filho, L. Nguyen
Journal: Journal of Thoracic Oncology (2019)
MA04.10 Development and Validation of a Gene Expression-Based Prognostic Signature in Early-Stage Squamous Cell Carcinoma of the Lung
Authors: P. Bose, A. Boylos, L. Petersen, O. Kovalchuk, I. Kovalchuk, M. Dean, D. Itani, K. Kopciuk, G. Bebb
Journal: Journal of Thoracic Oncology (2019)
EP1.12-07 High Discrepancy of Chemotherapy Outcomes Between Patients with Peripheral and Central Small Cell Lung Cancer
Authors: S. Mao, Q. Liu, Y. Liu, F. Zhou, S. Yang, Y. Wang, X. Yu, F. Wu, Y. He, X. Chen, C. Su, S. Ren, C. Zhou
Journal: Journal of Thoracic Oncology (2019)
JCSE01.22 Tumor Microenvironment Is Associated with Efficacy of PD-1/PD-L1 Inhibitors in Patients with Primary Pulmonary Lymphoepithelioma-Like Cancer
Authors: K. Yin, Z. Xie, Z. Lv, J. Yang, X. Yang, Q. Zhou, W. Zhong, L. Li, H. Feng, W. Guo, D. Lu, Y. Chen, W. Yan, Y. Wu, X. Zhang
Journal: Journal of Thoracic Oncology (2019)
EP1.05-02 Endobronchial Ultrasound and Transbronchial Needle Aspiration EBUS-TBNA: In a University Hospital in Latin America
Authors: L. Fernandez-Trujillo, E. Morales, J. Lores, M. Aguirre, A. Castro, L. Sua
Journal: Journal of Thoracic Oncology (2019)
Multi-component evaluation of minimum unit pricing in Scotland
Authors: Clare Beeston, Mark Robinson, Neil Craig, Lucie Giles
Journal: BMJ (2019)

O’Donnell and colleagues provide useful evidence of the short term effect of minimum unit pricing (MUP) on alcohol purchasing,1 and their research will make a useful contribution to the wider, independent evaluation being led by NHS Health Scotland on behalf of the Scottish government. Our evaluation will form the basis of the review required to inform a vote in Scottish …
P2.04-21 Serum CRP Decrease Has Predictive Value for Long-Term Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC
Authors: R. Matsuzawa, M. Morise, I. Tanaka, J. Koyama, T. Kimura, Y. Kondoh, T. Hase, K. Sakamoto, N. Hashimoto, Y. Hasegawa
Journal: Journal of Thoracic Oncology (2019)
P1.16-20 Trial in Progress: Cardiac Toxicity in Patients Undergoing Curative Intent Radiotherapy for Lung Cancer
Authors: K. Banfill, F. Sun, A. Mcwilliam, A. Abravan, J. Lilley, B. Wheller, M. Schmitt, K. Franks, M. Van Herk, C. Faivre-Finn
Journal: Journal of Thoracic Oncology (2019)
EP1.16-41 Lung Lobectomy for Elderly Patients Over 85 Years Old Is a Risk of a Complication and Long-Term Hospitalization Compared with Sublobar Resection
Authors: K. Nakata, K. Suzawa, S. Toyooka, K. Araki, S. Miyauchi, A. Miura, M. Okazaki, H. Yamamoto
Journal: Journal of Thoracic Oncology (2019)
A Case of Ruptured Uterus
Authors: J. M. Bryan
Journal: BMJ (1870)

Inclusion body myositis is a chronic progressive myopathy which tends not to respond to steroids and immunosuppressive treatments. Dysphagia is more common in this group than other inflammatory myopathies like polymyositis and dermatomyositis. Otolaryngologists are involved in the management of dysphagia in inclusion body myositis. They usually use a combination of cricopharyngeal myotomy, upper oesophageal dilation or botulinum injection to help with the symptoms. Cricopharyngeus myotomy is the preferred treatment in this group and patients tend to be discharged after a short stay in the hospital. However, our experience was completely different from what we expected as a relatively straightforward procedure led to severe morbidity and prolonged hospital admission due to continuous acid reflux and aspiration. We believe that the presence of hiatus hernia led to this problem as the patient9s problem resolved completely after her hernia was treated.
Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study,
Authors: Eri Matsuki, Yukako Ono, Masatoshi Sakurai, Hiroyoshi Kunimoto, Jo Ishizawa, Takayuki Shimizu, Akiko Yamane, Maiko Matsushita, Kenji Yokoyama, Shinichiro Okamoto
Journal: Blood (2011)
EP1.04-02 Predictors of Lung Toxicity in First Line Pembrolizumb for Advanced NSCLC: An Interim Analysis of PRELUTOX Study
Authors: V. Bonti, M.A. Teriaca, D. Lavacchi, M. Perna, S. Caini, F. Mazzoni, V. Maragna, E. Rosi, F. Giannelli, D. Cozzi, L. Visani, A. Calabrò, M. Bartolucci, L.P. Ciccone, M. Mariotti, N. Flego, C.E. Comin, D. Pezzulla, C. Moroni, E. Cavigli, A. Bindi, G. Caramia, F. Meacci, V. Miele, F. Lavorini, L. Voltolini, L. Livi, V. Scotti, K. Ferrari
Journal: Journal of Thoracic Oncology (2019)
MA25.02 Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&amp;E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung Cancer
Authors: X. Wang, C. Barrera, K. Bera, C. Lu, M. Feldman, K. Schalper, D. Rimm, V. Velcheti, A. Madabhushi
Journal: Journal of Thoracic Oncology (2019)
P1.04-64 The Opposite Role of PD-L1 Expression in EGFR Mutant Lung Cancer Treated with PD-1 Inhibitor Before and After EGFR TKI: Pilot Study
Authors: H.S. Park, S.S. Cho, H.J. An, J. Yoo, B.Y. Shim, S.K. Kim, D.G. Cho, S.W. Kim, J.M. Ko, Y.H. Park, C.H. Kim
Journal: Journal of Thoracic Oncology (2019)
Real-Time Detection of PML-RARA and RARA-PML Fusion Transcripts in High Risk Acute Promyelocytic Leukemia (APL) Treated with Arsenic Trioxide (ATO): Implications for Realization of Pre-Emptive Therapy for Molecular Relapse.
Authors: David Grimwade, J.V. Jovanovic, D. Diverio, E. Nugent, A.Y. Ho, G.J. Mufti, R.K. Hills, E. Solomon, R.E. Clark, F. Lo Coco, A.K. Burnett
Journal: Blood (2006)
MA08.09 Results of Trimodality Therapy for Patients with cN2 Lung Cancer Diagnosed by Video-Assisted Mediastinoscopic Lymphadenectomy (VAMLA)
Authors: S. Call, C. Obiols, R. Rami-Porta, S. Catot, M. Nuñez, M. Campayo, F. Perez Ochoa, M. Serra-Mitjans, J. Belda-Sanchis
Journal: Journal of Thoracic Oncology (2019)
P1.04-56 Landscape of Tumor Mutational Burden in Indian NSCLC Patients
Authors: P. Mehta, B. Dhabhar, A. Bhatt, P. Dattatreya, A. Maru, R. Vijayakumar, V. Maniar, M. Basade, K. Patel, S. Alurkar, C. Bahl, S. Todur
Journal: Journal of Thoracic Oncology (2019)
A homogenous, high through-put luminescent cAMP assay to monitor modulation of Gs and Gi protein coupled receptors
Authors: Said A. Goueli, Meera Kumar, Kevin Hsiao, Jolanta Vidugiriene, Bob Bulleit
Journal: Cancer Research (2006)

1109  G Protein Coupled Receptors represent a large validated target for Drug discovery research. They are classified into three, main groups based on the G protein associated with the receptor. The Gs is coupled to activation of adenylate cyclase and Gi is coupled to inhibition of adenylate cyclase while Gq is coupled to activation of phospholipase beta. There are two main strategies to monitor the activation of GPCR, a reporter based assays and cAMP accumulation based assays. We report here on a new assay for monitoring modulation of GPCR that are linked to activation or inhibition of adenylate cyclase (Gs or Gi). The assay can be used to monitor cAMP accumulation or depletion in the cell upon treatment with agonists or antagonists of Gs or Gi coupled receptors. The assay is homogenous, and amenable to high through screening of modulators of GPCR. A value of Z’ higher than 0.7 attests to the robustness of the assay and is carried out in 96-, and 384-, well plates and potentially adaptable to 1536-well format. The assay is based on luminescence and thus it does not suffer from fluorescence interference of library compounds. We have successfully generated EC50 values for agonists and IC50 values for antagonists of Gs coupled receptors that are similar to those reported in the literature. The assay is easy to use, and can be carried out in less than 60 minutes and does not require antibodies or expensive instrumentation for signal detection. The signal output is relatively stable for few hours and thus can be used for screening large number of plates. This luminescent assay is fast, homogenous, and reliable as indicated by high Z’ values, making it an attractive screening tool for identifying agonist or antagonists that modulate Gs and Gi coupled receptors.
P2.01-07 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1-Containing Therapy (HUDSON)
Authors: S. Lao-Sirieix, J. Heymach, P. Forde, M. Thomas, K. Park, B. Besse, M. Awad, G. Goss, N. Rizvi, H. Ambrose, W. Hanekom, S. Fox, P. Jewsbury, G. Pouliot, P. Mortimer, S. Patel, K. Sachsenmeier, J.c. Barrett, M. Stuart, Z. Szucs, L. Walton
Journal: Journal of Thoracic Oncology (2019)
Myeloid-derived suppressor cells in hematological malignancies: friends or foes
Authors: Meng Lv, Ke Wang, Xiao-jun Huang
Journal: Journal of Hematology & Oncology (2019)

Abstract Myeloid-derived suppressor cells (MDSCs) are newly identified immature myeloid cells that are characterized by the ability to suppress immune responses and expand during cancer, infection, and inflammatory diseases. Although MDSCs have attracted a lot of attention in the field of tumor immunology in recent years, little is known about their multiple roles in hematological malignancies as opposed to their roles in solid tumors. This review will help researchers better understand the various characteristics and functions of MDSCs, as well as the potential therapeutic applications of MDSCs in hematological malignancies, including lymphoma, multiple myeloma, leukemia, and hematopoietic stem cell transplantation.
P1.12-18 Nonclinical Safety Assessment of AMG 757, a DLL3 Bispecific T Cell Engager, in the Cynomolgus Monkey
Authors: E. Lobenhofer, J. Werner, M. Giffin, M. Engwall, R. Davies, O. Homann, M. Lafleur, G. Moffat
Journal: Journal of Thoracic Oncology (2019)
Stepped Care Internet-Delivered vs Face-to-Face Cognitive-Behavior Therapy for Pediatric Obsessive-Compulsive Disorder
Authors: Kristina Aspvall, Erik Andersson, Fabian Lenhard, Karin Melin, Lisa Norlin, Lena Wallin, Maria Silverberg-Mörse, Inna Feldman, Matteo Bottai, David Mataix-Cols, Eva Serlachius
Journal: JAMA Network Open (2019)

Internet-delivered cognitive behavior therapy is an effective treatment for children and adolescents with obsessive-compulsive disorder and has the potential to markedly increase access to treatment for patients while being cost-effective for health care organizations.To investigate whether internet-delivered cognitive behavior therapy implemented within a stepped care model is noninferior to, and cost-effective compared with, the gold standard of face-to-face cognitive behavior therapy for pediatric obsessive-compulsive disorder.Multicenter, single-blind, randomized clinical noninferiority trial implemented at 2 specialist pediatric obsessive-compulsive disorder clinics in Stockholm and Gothenburg, Sweden. Participants are 152 children and adolescents aged 7 to 17 years with obsessive compulsive disorder, recruited through the 2 clinics and online self-referral. Patients will be randomized 1:1 to the stepped care intervention or face-to-face therapy. Blind evaluations will be conducted after treatment and at 3-month and 6-month follow-ups. At the 6-month follow-up (primary end point), noninferiority will be tested and resource use will be compared between the 2 treatment groups. Data will be analyzed according to intention-to-treat principles.Patients randomized to stepped care will first receive internet-delivered cognitive behavior therapy for 16 weeks; patients who are classified as nonresponders 3 months after treatment completion will receive additional face-to-face therapy. The control group will receive 16 weeks of face-to-face cognitive behavior therapy immediately following randomization and nonresponders at the 3-month follow-up will, as in the stepped care group, receive additional face-to-face therapy.Noninferiority is defined as a 4-point difference on the primary outcome measure (Children's Yale-Brown Obsessive Compulsive Scale).Recruitment started October 6, 2017, and was completed May 24, 2019. Results from the primary end point will be available by May 2020. The naturalistic follow-ups (1, 2, and 5 years after the end of treatment) will continue to 2025. There are no interim analyses planned or stopping rules for the trial.ClinicalTrials.gov identifier: NCT03263546.
P1.04-62 Nomogram Based on Multivariable Regression Model Estimates the Overall Survival of Nivolumab for Previously Treated Advanced NSCLC
Authors: M. Tamiya, A. Tamiya, H. Go, T. Inoue, M. Kimura, K. Kunimasa, K. Nakahama, Y. Taniguchi, T. Shiroyama, S. Isa, K. Nishino, T. Kumagai, H. Suzuki, S. Atagi, T. Hirashima, A. Shintani, F. Imamura
Journal: Journal of Thoracic Oncology (2019)
P1.10-04 Lung Cancer in Patients with HIV Disease - Unique Clinical and Biomarker Features Impacting Lung Cancer Screening and Management
Authors: S. Attarian, X. Guo, B. Ko, A. Singh, E. Castellucci, R. Gucalp, M. Haigentz, H. Cheng, B. Halmos
Journal: Journal of Thoracic Oncology (2019)
P1.16-10 Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
Authors: A. Kuzminin, N. Minatta, M. Bluthgen, M. Rizzo, M. Naveira, V. Wainsztein, L. Lupinacci, M. Rizzi, M. Faura, A. Perfetti, G. Recondo
Journal: Journal of Thoracic Oncology (2019)
Early cidofovir administration might be associated with a lower probability of respiratory failure in treating human adenovirus pneumonia: a retrospective cohort study
Authors: J.-H. Ko, J.U. Lim, J.Y. Choi, H.S. Oh, H. Yoo, B.W. Jhun, K. Huh, K.R. Peck
Journal: Clinical Microbiology and Infection (2019)
P2.06-02 Mesothelioma Stratified Therapy (MiST): A Phase IIA Umbrella Trial for Accelerating the Development of Precision Medicines
Authors: D. Fennell, M. Hudka, L. Darlison, K. Lord, A. Bzura, J. Dzialo, C. Pritchard, J. Harber, T. Takata, S. Popat, M. Krebs, L. Nolan, A. Greystoke, C. Richards, P. Wells-Jordan, A. Branson, A. Gaba, V. Bhundia, M. Scotland, S. Mohamed, A. Dawson, C. Poille, C. Cowley, H. Walter, A. King, A. Thomas
Journal: Journal of Thoracic Oncology (2019)
P1.18-23 Use of Perfusion SPECT to Preserve Functional Lung in Radiotherapy for Non-Small-Cell Lung Cancer (NSCLC) Patients
Authors: S. Ramella, C. Greco, E. Ippolito, M. Fiore, S. Gentile, M. Miele, R. D'Angelillo
Journal: Journal of Thoracic Oncology (2019)
Loss of De Novo DNA Methyltransferase DNMT3A Impacts Alternative Splicing in Hematopoietic Stem Cells
Authors: Raghav Ramabadran, Jarey Wang, Anna Guzman, Sean Michael Cullen, Lorenzo Brunetti, Michael Gundry, Sunny Chan, Michael Kyba, Thomas Westbrook, Margaret Goodell
Journal: Blood (2017)
P2.01-04 NCI-NRG Oncology ALK PROTOCOL (NRG-LU003): A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients
Authors: S. Malik, C. Hu, A. Shaw, E. Korn, A. Tsao, R. Doebele, T. Stinchcombe, C. Lovly, J. Bradley
Journal: Journal of Thoracic Oncology (2019)
Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.
Authors: Andreas Hochhaus, Martin C Müller, Jerald Radich, Susan Branford, Benjamin Hanfstein, Philippe Rousselot, Jeffrey H Lipton, Eric Bleickardt, Ritwik Sinha, Timothy P Hughes
Journal: Blood (2008)
Simultaneous resection of pancreatic cancer and liver oligometastases after induction chemotherapy in stage IV patients: An open-label prospective randomized multicenter phase III trial (CSPAC-1)
Authors: M. Wei, S. Shi, J. Xu, B. Shen, Y. Mou, R. Qin, W. Fang, R. Chen, W. Wang, C. Shao, X. Yu
Journal: Annals of Oncology (2019)
MA01.10 Additional Local Consolidative Therapy Showed Survival Benefit Than EGFR-TKIs Alone in Bone Oligometastatic Lung Adenocarcinoma Patients
Authors: F. Hu, C. Li, J. Xu, J. Guo, Y. Shen, W. Nie, X. Zheng, L. Wang, H. Zhang, B. Han, X. Zhang
Journal: Journal of Thoracic Oncology (2019)
P2.06-12 Dysphagia in Patients with Malignant Pleural Mesothelioma (MPM)
Authors: M. Malec, A. Desai, I. Waxman, T. Karrison, B. Rose, A. Mendoza, M. Gadiraju, C. Straus, J. Churpek, H. Kindler
Journal: Journal of Thoracic Oncology (2019)
P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
Authors: R. Herbst, F. Barlesi, L. Paz-Ares, D. Raben, C. Aggarwal, J. Bothos, R. Samadani, P. He, N. Angra, P. Martinez
Journal: Journal of Thoracic Oncology (2019)
Antihypertensive Medication Use in Older Adults at Risk for Hip Fracture
Authors: Karen L. Margolis
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MA13.01 Associations Between Baseline Serum Biomarker Levels and Cachexia/Pre-Cachexia in Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: G. Lobato, M.J. Fidler, J. Fialkoff, M. Multani, C. Wakefield, S. Basu, M. Batus, P. Bonomi, J. Borgia
Journal: Journal of Thoracic Oncology (2019)
OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial
Authors: N. Baize, I. Monnet, L. Greillier, M. Geier, H. Lena, H. Janicot, A. Vergnenegre, J. Crequit, R. Lamy, J.B. Auliac, J. Le Treut, H. Le Caer, R. Gervais, E. Dansin, A. Madroszyk, P. Renault, G. Legarff, R. Schott, P. Saulnier, C. Chouaid
Journal: Journal of Thoracic Oncology (2019)
Mechanically Disaggregated Unfixed Trephine Biopsies Can be Used for Diagnostic Immunophenotyping in Acute Leukaemia
Authors: David Taussig, Ricardo Morilla, Alison Morilla, Kate Moss, Veselka Nikolova, Kelly Marquardt, Sophie Duke, Kasia Adamowska, Lynnsay Fuller, Ala Taifoor, Naomi Johnson, Athanasia Zeisig, Ayad Atra
Journal: Blood (2017)
P1.06-16 Molecular Signature in Malignant Pleural Mesothelioma (MPM). Preliminary Data of Rames Study
Authors: M. Pagano, F. Zanelli, R. Gnoni, C. Bonelli, M. Tiseo, G. Pasello, F. Grosso, M. Garassino, H. Soto Parra, P. Zucali, C. Giovanni Luca, F. Torricelli, A. Ciarrocchi, M. Larocca, M. D'Arcangelo, C. Pinto
Journal: Journal of Thoracic Oncology (2019)
P2.03-20 Potent in Vitro Activity of Tarloxotinib for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance
Authors: T. Koga, K. Suda, M. Nishino, T. Fujino, S. Ohara, J. Soh, A. Vellanki, V. Tirunagaru, T. Misudomi
Journal: Journal of Thoracic Oncology (2019)
Social prescribing gets its own academy
Authors: Abi Rimmer
Journal: BMJ (2019)

A new charity will develop best practice and training in social prescribing, the UK government has said.

The Department of Health and Social Care said that the National Academy for Social Prescribing would benefit patients with long term health problems by helping healthcare professionals to prescribe arts, sports, and leisure activities.

Announcing the creation of the academy on 23 October, …
Usefulness of a clutch cutter combined with an S-O clip in improving stability when opening the pocket in the pocket-creation method
Authors: Satoshi Abiko, Ayumu Yoshikawa, Kazuaki Harada, Naoki Kawagishi, Itsuki Sano, Hisashi Oda, Takuto Miyagishima
Journal: Endoscopy (2019)

The pocket-creation method (PCM) is a useful resection technique that has been developed to overcome difficulties in colorectal endoscopic submucosal dissection (ESD) [1] [2]. However, this technique itself poses certain challenges in resection when opening the pocket, particularly when there are considerable respiratory changes. Here, we report the usefulness of combining a clutch cutter [3] – a scissor-type knife – with an S-O clip [4] for overcoming instability when opening the pocket in the PCM.
P1.16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort
Authors: G. Metro, D. Signorelli, J. Rey-Cobo, M. Banini, P. Economopoulou, G. Lo Russo, P. Baxevanos, F. Roila, A. De Toma, G. Banna, A. Christopoulou, B. Jimenez, A. Collazo-Lorduy, H. Linardou, A. Calles Blanco, D. Galetta, A. Addeo, A. Camerini, P. Kosmidis, M. Garassino, G. Mountzios
Journal: Journal of Thoracic Oncology (2019)
MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies
Authors: J. Zhang, C. Zhou, Y. Zhao, X. Mu, J. Zhou, Z. Bao, Y. Fan, Y. Xu, Y. Shu, R. Guo, X. Liu, H. Wang, H. Zhang, L. Deng, N. Ma, J. He, Y. Zhang, M. Chen, Y. Jiang
Journal: Journal of Thoracic Oncology (2019)